Redispersible lipid nanoparticles of Spironolactone obtained by three drying methods

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 413, Issue , 2012, Pages 191-199

  Bourezg, Zouaoui ^a   Bourgeois, Sandrine ^a,b   Pressenda, Sara ^a   Shehada, Tharwa ^a   Fessi, Hatem ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Fluid bed drying; Freeze drying; Lipid nanoparticles; Pediatric dosage form; Spironolactone; Spray drying

Indexed keywords

BIOCHEMISTRY; DISSOLUTION; PEDIATRICS; SPRAY DRYING;

DOSAGE FORMS; FLUID BED DRYING; FREEZE DRYING; LIPID NANOPARTICLES; SPIRONOLACTONE;

NANOPARTICLES;

LIPID; NANOPARTICLE; SPIRONOLACTONE;

AEROSOL; ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FREEZE DRYING; POWDER; PRIORITY JOURNAL;

EID: 84867100730     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2012.03.027     Document Type: Article

References (67)

1. Fortwengel G., Ostermann H., Staudinger R. Better medicines for children: clinical investigation of medicinal products in the paediatric population - a QA perspective. Qual. Assur. J. 2007, 11:123-127.
2. EMA Committee for Medicinal Products for Human Use (CHMP) Reflection Paper: Formulations of Choice for the Paediatric Population 2006.
3. Royal College of Paediatrics and Child Health Safer and Better Medicines for Children 2004.
4. O'Neil M.J. The Merck Index an Encyclopedia of Chemicals, Drugs, and Biologicals 2006, Merck, Whitehouse Station, NJ.
5. Vidal 2011 le dictionnaire (Vidal: Issy-les-Moulineaux, 2011).
6. Yusuff N., York P. Spironolactone-cyclodextrin complexes: phase solubility and ultrafiltration studies. Int. J. Pharm. 1991, 73:9-15.
7. Berbenni V., et al. Physico-chemical characterisation of different solid forms of Spironolactone. Thermochim. Acta 1999, 340:117-129.
8. Langguth P., et al. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using Spironolactone as model compound. Drug Dev. Ind. Pharm. 2005, 31:319-329.
9. Dong Y., Ng W.K., Shen S., Kim S., Tan R.B.H. Preparation and characterization of Spironolactone nanoparticles by antisolvent precipitation. Int. J. Pharm. 2009, 375:84-88.
10. Laouini A., Jaafar-Maalej C., Sfar S., Charcosset C., Fessi H. Liposome preparation using a hollow fiber membrane contactor - application to Spironolactone encapsulation. Int. J. Pharm. 2011, 415:53-61.
11. Yassin A.E.B., et al. Preparation and characterization of Spironolactone-loaded gelucire microparticles using spray-drying technique. Drug Dev. Ind. Pharm. 2009, 35:297-304.
12. Kaukonen A., Vuorela P., Vuorela H., Mannermaa J.P. High-performance liquid chromatography methods for the separation and quantitation of Spironolactone and its degradation products in aqueous formulations and of its metabolites in rat serum. J. Chromatogr. A 1998, 797:271-281.
13. Kaukonen A.M., Kilpelainen I., Mannermaa J.P. Water-soluble [beta]-cyclodextrins in paediatric oral solutions of Spironolactone: solubilization and stability of Spironolactone in solutions of [beta]-cyclodextrin derivatives. Int. J. Pharm. 1997, 159:159-170.
14. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
15. Kamiya S., et al. Preparation and stabilization of nifedipine lipid nanoparticles. Int. J. Pharm. 2008, 354:242-247.
16. ®) for oral drug delivery. Drug Dev. Ind. Pharm. 2008, 34:1394-1405.
17. Müller R., Radtke M., Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002, 242:121-128.
18. Pardeike J., Hommoss A., Müller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366:170-184.
19. Li X., et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm. 2008, 363:177-182.
20. Hu F. Preparation and characterization of solid lipid nanoparticles containing peptide. Int. J. Pharm. 2004, 273:29-35.
21. García-Fuentes M., Torres D., Alonso M. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid Surf. B 2003, 27:159-168.
22. Lopes R., Eleutério C.V., Gonçalves L.M.D., Cruz M.E.M., Almeida A.J. Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur. J. Pharm. Sci. 2012, 45:442-450.
23. Müller R., Keck C.M. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 2004, 113:151-170.
24. Jensen L.B., et al. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int. J. Pharm. 2010, 390:53-60.
25. Kang K.W., et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010, 6:210-213.
26. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
27. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24:4283-4300.
28. Souto E.B., Müller R.H. SLN and NLC for topical delivery of ketoconazole. J. Microencapsul. 2005, 22:501-510.
29. Radomskasoukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59:411-418.
30. Freitas C., Müller R.H. Spray-drying of solid lipid nanoparticles (SLNTM). Eur. J. Pharm. Biopharm. 1998, 46:145-151.
31. Ohshima H., et al. Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution. Int. J. Pharm. 2009, 377:180-184.
32. Yamamoto K., Jesse Shao Z. Process development, optimization and scale-up: fluid-bed granulation. Developing Oral Dosage Forms, Pharmaceutical Theory and Practice 2009, Academic Press, USA. Y. Qiu, Y. Chen, G.Z. Zhang (Eds.).
33. Sansone F., et al. Maltodextrin/pectin microparticles by spray drying as carrier for nutraceutical extracts. J. Food Eng. 2011, 105:468-476.
34. Truong V., Bhandari B.R., Howes T. Optimization of co-current spray drying process of sugar-rich foods. Part I - moisture and glass transition temperature profile during drying. J. Food Eng. 2005, 71:55-65.
35. Tsinontides S., et al. Freeze drying -principles and practice for successful scale-up to manufacturing. Int. J. Pharm. 2004, 280:1-16.
36. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 2006, 58:1688-1713.
37. Vighi E., Ruozi B., Montanari M., Battini R., Leo E. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur. J. Pharm. Biopharm. 2007, 67:320-328.
38. R. Pacheco, J. Omar, Advisor: Velazquez Figueroa, Carlos School University of Puerto Rico, Mayaguez, Optimization of a Fluid Bed Dryer by the Implementation of a Model Predictive Controller, 2007.
39. Chan H.K., Kwok P.C.L. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
40. Wan Daud W.R. Fluidized bed dryers recent advances. Adv. Powder Technol. 2008, 19:403-418.
41. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 2000, 11(Suppl. 2):93-98.
42. Rowe R.C., Sheskey P.J., Quinn M. Handbook of Pharmaceutical Excipients 2009, Pharmaceutical Press.
43. C. Nutrition, for F.S. and A. GRAS Notice Inventory (last accessed 03.03.12) http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRASListings/default.htm.
44. Buse J., El-Aneed A. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. Nanomedicine 2010, 5:1237-1260.
45. Battaglia L., et al. Methotrexate-loaded SLNs prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution. Nanomedicine 2011, 6:1561-1573.
46. Yu Y.H., et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur. J. Pharm. Biopharm. 2012, 80:268-273.
47. Müller R.H. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
48. Galvin P., et al. Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cell. Mol. Life Sci. 2012, 69:389-404.
49. Puri A., et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 2010, 26:523-580.
50. Sharma A., Madhunapantula S.V., Robertson G.P. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert. Opin. Drug Metab. Toxicol. 2012, 8:47-69.
51. Conti M., et al. Anticancer drug delivery with nanoparticles. In Vivo 2006, 20:697-701.
52. Yan F., et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake and cytotoxicity. Nanomed.: Nanotechnol. Biol. Med. 2010, 6:170-178.
53. Müller R.H., Schwarz C., Zur M. Incorporation of lipo-philic drugs and drug release profiles of solid lipid nanoparticles (SLN). Proc. Int. Symp. Control. Release Bioact. Mater. 1994, 21:146-147.
54. Zur Mühlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149-155.
55. Bolhuis G.K., Rexwinkel E.G., Zuurman K. Polyols as filler-binders for disintegrating tablets prepared by direct compaction. Drug Dev. Ind. Pharm. 2009, 35:671-677.
56. Arnum P.V. Pediatric formulations: technical and regulatory considerations. Pharm. Technol. 2009, (last accessed 03.03.12) http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=615617.
57. Davies E., Tuleu C. Medicines for children: a matter of taste. J. Pediatr. 2008, 153:599-604.
58. Doty R.L., Shah M., Bromley S.M. Drug-induce taste disorders. Drug Saf. 2008, 31:199-215.
59. Schiffman S.S. Critical illness and changes in sensory perception. Proc. Nutr. Soc. 2007, 66:331-345.
60. Willart J.F., et al. Polymorphic transformation of the [Gamma]-form of d-sorbitol upon milling: structural and nanostructural analyses. Solid State Commun. 2005, 135:519-524.
61. Nezzal A., Aerts L., Verspaille M., Henderickx G., Redl A. Polymorphism of sorbitol. J. Cryst. Growth 2009, 311:3863-3870.
62. Broadhead J., Edmond Rouan S.K., Rhodes C.T. The spay drying of pharmaceutics. Drug Dev. Ind. Pharm. 1992, 18:1169-1206.
63. Schwarz C., Mehnert W., Lucks J.S., Müller R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control. Release 1994, 30:83-96.
64. Müller R.H., Mehnert W., Lucks J.S., Schwarz C., Zur M. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 1995, 41:62-69.
65. Federman N., Denny C.T. Targeting liposomes toward novel pediatric anticancer therapeutics. Pediatr. Res. 2010, 67:514-519.
66. Dobson J. Toxicological aspects and applications of nanoparticles in paediatric respiratory disease. Paediatr. Respir. Rev. 2007, 8:62-66.
67. Abdelbary G., Fahmy R.H. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS Pharm. Sci. Technol. 2009, 10:211-219.